Sysco (SYY) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.39 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +5.71%. A quarter ago, it was expected that this food distributor would post earnings of $1.03 per share when it actually produced earnings of $0.96, delivering a surprise of -6.8%. Over the last four quarters, the company h ...

分组1 - Exagen Inc. reported a quarterly loss of $0.18 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.16 per share a year ago [1] - The company posted revenues of $17.2 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 7.51%, and up from $15.06 million year-over-year [2] - Exagen shares have increased approximately 80.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] 分组2 - The earnings outlook for Exagen is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Exagen was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $16.5 million, and -$0.61 on revenues of $65.8 million for the current fiscal year [7] 分组3 - The Medical - Products industry, to which Exagen belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, which may impact stock performance [8] - Cresco Labs Inc., another company in the same industry, is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +75%, with revenues projected at $163.86 million, down 11.1% from the previous year [9]

分组1 - Alkermes reported quarterly earnings of $0.52 per share, exceeding the Zacks Consensus Estimate of $0.41 per share, but down from $0.72 per share a year ago, representing an earnings surprise of +26.83% [1] - The company posted revenues of $390.66 million for the quarter, surpassing the Zacks Consensus Estimate by 15.38%, although this is a decrease from year-ago revenues of $399.13 million [2] - Over the last four quarters, Alkermes has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] 分组2 - The stock has underperformed the market, losing about 9.1% since the beginning of the year compared to the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the coming quarter is $0.48 on revenues of $353.2 million, and for the current fiscal year, it is $1.81 on revenues of $1.37 billion [7] - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently in the top 38% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - Shutterstock reported quarterly earnings of $1.19 per share, missing the Zacks Consensus Estimate of $1.65 per share, and showing an increase from $1 per share a year ago [1] - The company posted revenues of $266.99 million for the quarter, missing the Zacks Consensus Estimate by 2.83%, and up from $220.05 million year-over-year [3] Earnings Performance - The earnings surprise for the quarter was -27.88%, with the company having surpassed consensus EPS estimates only once in the last four quarters [2] - The previous quarter also saw a negative surprise, with actual earnings of $1.03 per share against an expectation of $1.26, resulting in a surprise of -18.25% [2] Stock Performance - Shutterstock shares have declined approximately 34.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [4] - The current Zacks Rank for Shutterstock is 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.47 on revenues of $268.97 million, and for the current fiscal year, it is $5.39 on revenues of $1.07 billion [8] - The outlook for the industry, particularly the Internet - Content sector, is currently in the bottom 30% of Zacks industries, which may impact stock performance [9]

Royal Caribbean (RCL) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.1 per share. This compares to earnings of $3.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +6.83%. A quarter ago, it was expected that this cruise operator would post earnings of $2.53 per share when it actually produced earnings of $2.71, delivering a surprise of +7.11%. Over the last four quarters, the ...

Core Viewpoint - UnitedHealth Group reported quarterly earnings of $4.08 per share, missing the Zacks Consensus Estimate of $4.84 per share, and down from $6.8 per share a year ago, indicating an earnings surprise of -15.70% [1][2] Financial Performance - The company posted revenues of $111.62 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.06%, and up from $98.86 billion year-over-year [2] - Over the last four quarters, UnitedHealth has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - UnitedHealth shares have declined approximately 44.2% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for UnitedHealth is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.93 on revenues of $113.13 billion, and for the current fiscal year, it is $21.15 on revenues of $448.53 billion [7] - The trend of estimate revisions for UnitedHealth was unfavorable prior to the earnings release, which may impact future stock movements [5][6] Industry Context - The Medical - HMOs industry, to which UnitedHealth belongs, is currently in the bottom 4% of the Zacks industry rankings, suggesting potential challenges ahead [8] - The performance of UnitedHealth's stock may be influenced by the overall outlook for the industry [8]

Group 1 - The company has slightly raised its adjusted operating margin forecast, now expecting it to be between 11.3% and 11.8%, an increase of 50 basis points from previous expectations [1] - In the second quarter, the company's sales grew by 1% year-on-year, reaching €4.3 billion (approximately $4.98 billion) [1] - The company had previously lowered its annual profit forecast in May, attributing it to costs associated with tariffs, estimating potential losses of up to €300 million [1] Group 2 - A report from February indicated that the company paid €38 million in tariffs in the U.S. last year, highlighting the significant impact of tariffs on its operations [2] - The U.S. is the company's largest market, expected to account for about 40% of its sales in 2024, with one-third of its tax payments coming from this market [2] - The company imports various products from China, including respiratory masks and electric shavers, while also sourcing medical equipment from Europe [2]

Company Performance - HomeStreet reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, representing an earnings surprise of -420.00% [1] - The company posted revenues of $48.97 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.87%, and showing an increase from $42.93 million year-over-year [2] - Over the last four quarters, HomeStreet has not been able to surpass consensus EPS estimates, although it has topped consensus revenue estimates twice [2] Stock Outlook - HomeStreet shares have increased by approximately 16% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $0.12 on $50 million in revenues, and $0.16 on $194.65 million in revenues for the current fiscal year [7] Industry Context - The Financial - Savings and Loan industry, to which HomeStreet belongs, is currently in the bottom 30% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact HomeStreet's stock performance [5][6]

Company Performance - Nucor reported quarterly earnings of $2.6 per share, missing the Zacks Consensus Estimate of $2.62 per share, and down from $2.68 per share a year ago, representing an earnings surprise of -0.76% [1] - The company posted revenues of $8.46 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.61% and up from $8.08 billion year-over-year [2] - Over the last four quarters, Nucor has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - Nucor shares have increased approximately 25% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is $2.56 on revenues of $7.97 billion, and for the current fiscal year, it is $8.21 on revenues of $31.82 billion [7] Industry Outlook - The Steel - Producers industry, to which Nucor belongs, is currently ranked in the bottom 13% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Nucor's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

分组1 - Universal Health Services (UHS) reported quarterly earnings of $5.35 per share, exceeding the Zacks Consensus Estimate of $4.85 per share, and showing an increase from $4.31 per share a year ago, resulting in an earnings surprise of +10.31% [1] - The company achieved revenues of $4.28 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.51%, and up from $3.91 billion year-over-year [2] - Over the last four quarters, UHS has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] 分组2 - The stock has underperformed the market, losing about 13.3% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is $4.36 on revenues of $4.31 billion, and for the current fiscal year, it is $19.43 on revenues of $17.09 billion [7] - The Zacks Industry Rank for Medical - Hospital is currently in the bottom 26% of over 250 Zacks industries, indicating potential challenges for stock performance [8]